All News

2018

September

Media Release / Sep 06, 2018

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Read More

July

Media Release / Jul 06, 2018

Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance

Read More
Media Release / Jul 01, 2018

Sandoz Inc. enters exclusive agreement to distribute and commercialize SYMJEPI™ (epinephrine) in the US

Read More

April

Media Release / Apr 18, 2018

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

Read More
Media Release / Apr 09, 2018

Sandoz US named one of the “Best and Brightest Companies to Work for in the Nation”

Read More

February

Media Release / Feb 13, 2018

Sandoz announces US FDA approval and launch of Glatopa® 40

Read More

January

Media Release / Jan 16, 2018

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

Read More
2017

November

Media Release / Nov 14, 2017

New data reinforces clinical basis for switching to Sandoz biosimilar medicines

Read More
Featured News / Nov 14, 2017

Sandoz is Leading the Way in Biosimilars

Biosimilars are an opportunity to help reduce the burden of rising treatment costs.

Read More
Media Release / Nov 06, 2017

Sandoz data confirms Erelzi™ biosimilar matches efficacy and safety profile of reference biologic in rheumatoid arthritis (RA)

Read More

Pages